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Abstract
Background—Urinary melatonin levels have been associated with a reduced risk of breast 
cancer in postmenopausal women, but this association might vary according to tumor melatonin 1 
receptor (MT1R) expression.
Methods—We conducted a nested case-control study among 1,354 postmenopausal women in 
the Nurses’ Health Study, who were cancer free when they provided first-morning spot urine 
samples in 2000–2002; urine samples were assayed for 6-sulfatoxymelatonin (aMT6s, a major 
metabolite of melatonin). Five-hundred fifty-five of these women developed breast cancer before 
May 31, 2012, and were matched to 799 control subjects. In a subset of cases, 
immunohistochemistry was used to determine MT1R status of tumor tissue. We used 
multivariable-adjusted conditional logistic regression to estimate the relative risk (RR) of breast 
cancer (with 95% confidence intervals [CI]) across quartiles of creatinine-standardized urinary 
aMT6s level, including by MT1R subtype.
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Results—Higher urinary melatonin levels were suggestively associated with a lower overall risk 
of breast cancer (multivariable-adjusted RR=0.78, 95% CI=0.61–0.99, comparing quartile 4 vs. 
quartile 1; p-trend=0.08); this association was similar for invasive vs. in situ tumors (p-
heterogeneity=0.12). There was no evidence that associations differed according to MT1R status 
of the tumor (e.g., p-heterogeneity for overall breast cancer=0.88).
Conclusion—Higher urinary melatonin levels were associated with reduced breast cancer risk in 
this cohort of postmenopausal women, and the association was not modified by MT1R subtype.
Impact—Urinary melatonin levels appear to predict the risk of breast cancer in postmenopausal 
women. However, future research should evaluate these associations with longer-term follow-up 
and among premenopausal women.
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INTRODUCTION
Light exposure during the biologic night has been hypothesized to increase risk of breast 
cancer(1). Melatonin, an indolamine hormone, is a molecular marker of the circadian 
system; it is entrained to the 24-hour environmental light-dark cycle, released by the pineal 
gland, and suppressed by light(2). In addition, melatonin has been shown to mediate 
numerous cell-signaling pathways involved in breast cancer, including estrogen-dependent 
pathways(3, 4). Some epidemiologic studies(5–7), although not all(8–11), have reported that 
lower levels of urinary melatonin are associated with greater risk of breast cancer—in line 
with the notion that light exposure at night, which suppresses melatonin secretion, promotes 
carcinogenesis.
Moreover, two melatonin receptors have been identified, melatonin 1 receptor (MT1R) and 
melatonin 2 receptor (MT2R), and MT1R has been found on the surface of breast tumors in 
cell culture(12–14). In rodents, MT1R overexpression has been linked to reduced breast 
tumor incidence(15), whereas age-related decline in MT1R expression has been shown to 
reduce the sensitivity of melatonin for these receptors, leading to enhanced tumor 
growth(16, 17). Indeed, experimental work indicates that melatonin’s anti-carcinogenic 
effects may be largely mediated by MT1R(18), but this potential mechanism has been under-
studied in human populations. In the Nurses’ Health Study, previous research found that 
higher urinary melatonin levels were strongly associated with lower risk of breast cancer 
based on 357 cases that developed over six years of follow up(7); however, the combined 
role of endogenous melatonin levels and MT1R in breast cancer has not been explored.
To extend our previous study, we evaluated the association of urinary melatonin and breast 
cancer risk in the Nurses’ Health Study, utilizing ~200 additional breast cancer cases with 
twice the length of follow-up. Furthermore, we examined whether this association differed 
according to MT1R status of the breast tumor.
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We conducted a nested case-control study within the Nurses’ Health Study (NHS) cohort. 
The NHS cohort began in 1976, when 121,701 female nurses, who were 30–55 years old and 
living in the United States, returned an initial mailed questionnaire with information on 
breast cancer risk factors and major medical diagnoses. This information has been updated 
using similar mailed questionnaires every two years, and participation has exceeded 90% at 
every questionnaire cycle. Between 2000 and 2002, 18,643 participants provided spot urine 
samples and completed a short supplemental questionnaire, including information on date 
and time of urine collection, confirmation of first-morning urine, current weight, and recent 
postmenopausal hormone (PMH) use; 93% of urine samples were first-morning samples. 
These samples were returned on ice, by overnight mail, after which they were aliquoted and 
stored in nitrogen freezers (at −130 degrees Celsius) until they were assayed for melatonin.
Women were eligible for the present analysis if they provided a urine sample and had no 
history of cancer (except non-melanoma skin cancer) prior to urine collection; cases were 
women who developed breast cancer after urine collection and before May 31, 2012. These 
cases were matched either 1:1 (for postmenopausal cases with recent PMH use) or 1:2 (all 
other cases) to controls who did not develop breast cancer during the follow-up period. 
Matching factors included: birth year, menopausal status, recent PMH use (defined as use ≤3 
months from the time of urine collection), timing of urine collection (month and time of 
day), and fasting status at urine collection. Women were considered postmenopausal if they 
reported natural menopause or bilateral oophorectomy, or if they reported hysterectomy 
without bilateral oophorectomy and were aged ≥56 years and a non-smoker, or aged ≥54 
years and a current smoker (90% of women in the cohort had reached natural menopause by 
these ages). We focused on postmenopausal women in this study. The Institutional Review 
Board of Brigham and Women’s Hospital approved this study, and informed consent was 
implied by voluntary return of mailed questionnaires and biological specimens.
Breast cancer case ascertainment
Participants self reported a breast cancer diagnosis on one of the biennial cohort 
questionnaires. All self-reported cases were asked for permission to review their medical 
records, which provided confirmation of their diagnosis. When medical records were 
unavailable, breast cancer cases were defined as probable and included in the analysis if 
corroborated by phone interview or written confirmation from the participant. In some cases, 
breast cancer was reported during death follow-up, when family members or the postal 
service reported a participant’s death to study personnel. The National Death Index was 
reviewed after each questionnaire cycle to determine the status of women who were 
unresponsive to cohort questionnaires. In this cohort, self-reported breast cancer was >98% 
accurate compared to pathology reports(19).
Urinary melatonin assessment
Urine samples for breast cancer cases and controls were removed from the freezer 
simultaneously, handled identically, and each batch was shipped in one parcel. Three batches 
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were sent for laboratory analysis based on the biennial questionnaire cycle in which women 
reported incident breast cancer. The first batch (i.e., incident cases reported on the 2002 and 
2004 biennial questionnaires and their matched controls) and second batch (i.e., incident 
cases reported on the 2006 biennial questionnaire and their matched controls) were sent to 
the Endocrine Core Laboratory of M. Wilson (Yerkes National Primate Center at Emory 
University, Atlanta, GA). The third batch (i.e., incident cases reported on the 2008 and 2010 
biennial questionnaires and their matched controls) were sent to the Specialty Assay 
Research Core Laboratory of R. Carroll (Brigham and Women’s Hospital, Boston, MA). 6-
sulfatoxymelatonin (aMT6s) was assayed using the Buhlmann enzyme-linked 
immunosorbent assay (ELISA), with a lower limit of detection of 0.8 ng/mL; creatinine 
levels were also assayed, which enabled creatinine standardization to account for differences 
in urine concentration. Laboratory personnel were blinded to case-control status, and case-
control samples were assayed together on the same day and in the same run; quality control 
samples were included in each batch. In the present analyses, within-batch coefficients of 
variation were: 9.5%, 10.3%, and 6.2% for aMT6s and 8.5%, 3.1%, and 1.1% for creatinine 
across the three batches, respectively.
The reproducibility of creatinine-adjusted aMT6s levels over three years has been previously 
established, using the collection and assessment method described for this cohort (intraclass 
correlation=0.72)(20).
MT1 receptor assessment
A detailed description of the breast tumor tissue block collection, microarrays (TMAs) 
construction, and immunohistochemical analyses performed can be found elsewhere(21–23). 
Briefly, we collected archived formalin-fixed, paraffin-embedded breast cancer blocks from 
incident breast cancer cases through 2006. Hematoxylin and eosin sections from those cases 
were reviewed to confirm the diagnosis, classify the cancer according to histological type 
and grade, and identify the area from which the cores for the TMAs would be taken. TMAs 
were constructed in the Dana-Farber Harvard Cancer Center Tissue Microarray Core Facility 
(Boston, Massachusetts). Three cores 0.6 mm in diameter were obtained from each breast 
cancer sample and inserted into the recipient TMA blocks.
Immunohistochemical staining for the MT1 receptor was performed on 5-μm paraffin 
sections cut from TMA blocks, using the following antibody: Melatonin Receptor (MT2/
MTNR1B) from LS Bio (Catalog #: LS-A930; Lot #: 7195/7196AP3-1; 1:1000 dilution). A 
maximum of three cores were reviewed for each tumor, and degree of MT1 receptor staining 
in the epithelium was assessed using image analysis software (Definiens, Carlsbad, CA). 
Mean staining across available cores was used to define the outcome; epithelial staining was 
scored as positive if the mean percentage of stained cells was ≥50%; it was otherwise 
considered negative. This cut point was determined by maximizing the accuracy of image 
analysis software results compared to those of an expert pathologist, who manually reviewed 
one of the TMAs (n=126 participants, with concordance of MT1R positive and negative 
ratings=89% and 79%, respectively). Because there is no established cut point for MT1R 
positivity, we also defined alternative cut points based on the absolute distribution of mean 
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epithelial staining (≤1/3, >1/3 to ≤2/3, and >2/3 of cells positive) and relative distribution of 
mean epithelial staining (in tertiles).
Statistical analysis
Of the 18,643 cohort participants with urine samples, 606 women without a prior history of 
cancer developed incident breast cancer during the follow-up period; they were matched to 
1,085 cancer-free controls. We excluded 279 women whose urine sample was not assayed 
for aMT6s, nine women whose aMT6s values were statistical outliers (according to the 
generalized extreme studentized deviate many-outlier detection approach(24)), and 23 
women who were not postmenopausal at the time of urine collection. In addition, we 
excluded 26 women whose matched pair was removed based on these exclusions. The 
remaining 1,354 women (555 breast cancer cases and 799 matched controls, with 158 
having MT1R subtype information) comprised our analytic sample.
For these analyses, aMT6s levels below the limit of detection (n=29) were conservatively set 
to 0.8 ng/mL (i.e., the lower limit of detection), and aMT6s levels were standardized to 
creatinine. Because absolute aMT6s levels assayed by the Wilson laboratory were 
consistently lower compared to the Carroll laboratory, we used a previously described 
method to recalibrate these measurements by accounting for batch-to-batch variability that 
was not explained by age and body-mass index (BMI) (i.e., the strongest predictors of 
aMT6s levels)(25, 26).
Using logistic regression models conditioned on matching factors, we estimated simple and 
multivariable-adjusted odds ratios to approximate relative risks [RR] of breast cancer (with 
corresponding 95% confidence intervals [CI]) across quartiles of creatinine-standardized 
urinary aMT6s levels (based on re-calibrated values). Our analyses extend a previous study 
of urinary melatonin and incident breast cancer in this cohort, which included follow-up 
time up until May 31, 2006(7); thus, to facilitate a comparison with previous findings, we 
also calculated effect estimates based on the second half of follow up (i.e., cases occurring 
between June 1, 2006 and May 31, 2012, and their matched controls). In the subset of case-
control pairs for which MT1R subtyping was available in the cases, we obtained separate 
estimates for MT1R-positive vs. negative tumors (defined as a tumor with ≥50%vs. <50 
percent of cells with MT1R staining) using similar models. We used batch-corrected 
quartiles based on the creatinine-standardized aMT6s distribution in the controls; the lowest 
quartile served as the reference category. Tests of linear trend were calculated across 
quartiles using the Wald statistic, and tests of heterogeneity were calculated across breast 
cancer subtypes (invasive vs. in situ and MT1R-positive vs. negative) using polytomous 
conditional logistic regression.
Multivariable-adjusted models were controlled for possible breast cancer risk factors: age at 
menarche (<12, 12, 13, ≥14 years), age at menopause (≤45, 46–50, 51–53, ≥54 years), parity 
(nulliparous, 1–2, 3–4, or ≥5 children), family history of breast cancer (mother or sister: yes, 
no), (BMI continuous in kg/m2), alcohol intake (0, 1–14.9, ≥15 g/day), smoking status 
(current: yes, no), history of benign breast disease (yes, no), PMH use (current: yes, no), and 
type and duration of PMH use (estrogen-only: 0, <5, ≥5 years; estrogen + progesterone: 0, 
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<5, ≥5 years). Antidepressant use (current: yes, no) and first morning urine (yes, no) 
variables were included in our models to reduce variation in urinary melatonin levels.
We conducted several secondary analyses. First, we repeated our overall analysis of urinary 
melatonin and incident breast cancer while restricting to women with first-morning urine 
samples. Second, we repeated our analysis restricting our sample to estrogen- and 
progesterone-positive cases (i.e., the majority of breast cancer cases in our sample) because 
melatonin might influence breast cancer development via hormone-dependent pathways(3, 
4). Third, we re-evaluated the association between urinary melatonin and incident breast 
cancer while implementing a two-year lag between time of urine collection and breast 
cancer diagnosis to minimize the possibility of subclinical breast tumors affecting urinary 
melatonin levels. Finally, in analyses incorporating the MT1R status of breast tumors, we 
explored alternative categories for defining MT1R-positivity (low, medium, and high) based 
on the absolute and relative distributions of mean epithelial staining, as described above.
Statistical tests were two sided and were considered statistically significant at p<0.05. All 
analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
When we examined the distribution of breast cancer risk factors, we observed several 
expected patterns in our sample: breast cancer cases were more likely to have a family 
history of breast cancer, and a history of benign breast disease compared to controls (Table 
1). In addition, cases had a higher mean intake of alcohol relative to controls. Among 158 
cases with MT1R subtyping, women with MT1R-positive tumors were less likely to be 
current smokers, recent PMH users, and estrogen-only PMH users for ≥5 years compared to 
women with MT1R-negative tumors; MT1R-positive cases also had higher alcohol 
consumption compared to MT1R-negative cases.
There were few meaningful differences in participant characteristics at the time of urine 
collection according to quartiles of urinary melatonin level; however, as expected, mean age 
and BMI decreased across increasing melatonin quartiles (Table 2).
In our main analyses, we observed a suggestive trend of decreasing risk of overall breast 
cancer (including invasive and in situ cases) across increasing melatonin quartiles during a 
mean of 4.0 years of follow up in simple and multivariable-adjusted models (p-trend=0.08 
for both models) (Table 3). Point estimates were similar in simple vs. multivariable-adjusted 
models, with significantly reduced risk comparing quartile 4 vs. quartile 1 in the fully-
adjusted model (i.e., the 95% CI for this comparison did not include the null value of 1.00) 
(RR=0.78 95% CI=0.61–0.99). When we examined invasive and in situ cases separately, 
there were similar trends with decreasing risk of breast cancer observed over increasing 
quartiles of melatonin (p-heterogeneity=0.12), although neither of these individual trends 
reached statistical significance (p-trend for final models=0.19 for invasive cases and 0.09 for 
in situ cases). When we evaluated these associations based on cases occurring during the 
second half of follow up (and their matched controls), we found that urinary melatonin 
levels were not related to risk of breast cancer during that period (multivariable-adjusted RR: 
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1.05, 95% CI: 0.66–1.67 comparing quartile 4 vs. quartile 1 of urinary melatonin, p-
trend=0.75) (Supplemental Table).
In the subset of 158 case-control pairs with MT1R subtyping in the cases, we found a similar 
pattern of overall association between urinary melatonin and breast cancer (Table 4). In 
multivariable-adjusted models, associations were also similar when we separately examined 
MT1R-negative cases (RR=0.60, 95% CI=0.35–1.06 comparing tertile 3 vs. tertile 1, p-
trend=0.07) and MT1R-positive cases (RR=0.76, 95% CI=0.39–1.51 comparing tertile 3 vs. 
tertile 1, p-trend=0.39) (p-heterogeneity=0.88). When we restricted to invasive cases only 
(there were not enough in situ cases to examine them separately), these results were largely 
unchanged, and there were no differences of association found comparing MT1R-positive 
vs. negative cases (p-heterogeneity=0.57).
In secondary analyses, our results were very similar when we restricted our analysis of 
urinary melatonin and incident breast cancer to women with first-morning urine samples 
(multivariable-adjusted estimate comparing quartile 4 vs. quartile 1 of urinary melatonin: 
RR=0.79, 95% CI=0.61–1.03, p-trend=0.09). Results were also similar when we examined 
estrogen- and progesterone-positive cases only (multivariable-adjusted estimate comparing 
quartile 4 vs. quartile 1 of urinary melatonin: RR=0.82, 95% CI=0.60–1.11, p-trend=0.19), 
and after excluding cases diagnosed within two years of urine collection (multivariable-
adjusted estimate comparing quartile 4 vs. quartile 1 of urinary melatonin: RR=0.79, 95% 
CI=0.58–1.06, p-trend=0.22) (data not shown in tables). For analyses based on MT1R status 
of tumors, results were similar when we utilized alternative cut points for the definition of 
MT1R positivity. For example, use of cut points based on absolute values of the distribution 
yielded the following results: multivariable-adjusted estimates comparing tertile 3 vs. tertile 
1 of urinary melatonin: RR=0.59, 95% CI=0.21–1.65, p-trend=0.41, for low MT1R 
positivity; RR=0.67, 95% CI=0.33–1.33, p-trend=0.14, for medium MT1R positivity; 
RR=1.00, 95% CI=0.44–2.29, p-trend=0.90, for high MT1R positivity; p-
heterogeneity=0.80) (data not shown in tables).
DISCUSSION
Overall, we found a suggestion that higher levels of urinary melatonin were related to lower 
risk of breast cancer risk over twelve years of follow up, which is consistent with previous 
findings with shorter follow up in this cohort. However, this association appeared to be 
driven by results from the first half of follow up, as there was no association between 
melatonin levels and breast cancer risk during the second half of follow up. In a subset of 
women with MT1R subtyping, we found no evidence that the association between urinary 
melatonin and incident breast cancer differed comparing MT1R-positive vs. negative 
tumors. To our knowledge, this is the first epidemiologic study to evaluate this association 
according to MT1R subtype of the breast tumor.
Two recent meta-analyses reported that higher levels of urinary melatonin were associated 
with a reduced risk of breast cancer in women based on published studies(27, 28). The 
summary relative risk of one meta-analysis indicated an approximately 18% decreased risk 
comparing quantile 4 vs. quartile 1 of urinary melatonin, with borderline significance 
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(RR=0.82, 95% CI=0.68–0.99)(27); this is very similar to the 22% risk reduction that we 
identified comparing quartile 4 vs. quartile 1 in our present study (OR=0.78, 95% CI=0.61–
0.99). Results of the second meta-analysis are also similar to our results, with an inverse 
association observed between urinary melatonin and breast cancer incidence, which 
appeared to be confined to postmenopausal women (RR=0.81 95% CI=0.70–0.92 for each 
15ng/mg creatinine increase in aMT6s)(28); however, the effect estimate comparing quantile 
4 vs. quartile 1 was not given, making it more difficult to compare these results to those of 
the present study.
Indeed, one of the studies included in these meta-analyses is our previous analysis of the 
association between urinary melatonin levels and breast cancer risk in the NHS cohort(7). 
With shorter follow up, our prior study identified a 38% lower risk of breast cancer among 
women in the quartile 4 vs. quartile 1 of urinary melatonin (RR=0.62, 95% CI=0.41–0.95); 
the p-trend was also highly significant (p=0.004), although the risk appeared to be equally 
lower in the top two quartiles. In addition, exclusion of breast cancer cases diagnosed within 
one to two years of urine collection somewhat attenuated the effect estimate and it became 
non-significant (RR=0.72, 95% CI=0.45–1.17, with a one-year lag; and RR=0.76, 95% 
CI=0.44–1.31, with a two-year lag). In the current study, we observed that this association 
was attenuated further and became null during the period six to twelve years after urine 
collection. Taken together, these results suggest that endogenous melatonin levels could 
influence breast cancer incidence in the shorter but not longer term.
With regard to the melatonin receptor, to date, few studies have assessed MT1R status of 
breast tumors in women. One study with MT1R information identified an association 
between MT1R positivity and survival among women with triple-negative breast cancer(29). 
These findings suggest that greater numbers of MT1R may be related to better outcomes in 
breast cancer, but more specific interpretation is difficult due to the lack of urinary melatonin 
assessment and restriction to triple-negative breast tumors in this population. More directly 
related to our analyses, a second study examined the association between melatonin receptor 
genes and breast cancer incidence in Chinese women, and results suggested that genotype 
might influence risk of breast cancer(30). Nonetheless, differences in genetic variation 
across different ethnic populations could limit the generalizability of these findings, and no 
additional studies have been undertaken in other ethnic populations. Although the current 
study does not suggest differences in the association between endogenous melatonin levels 
and breast cancer risk according to MT1R type, experimental evidence demonstrating an 
age-related decrease in sensitivity of these receptors for melatonin might explain this null 
finding(16, 17). Clearly, additional studies are needed to replicate our findings in 
postmenopausal women, as well as explore these associations in premenopausal women.
Our study is unique because it incorporates information on both urinary melatonin levels and 
MT1R subtype of breast tumors in women. An important limitation, however, is the 
relatively small number of women in our cohort (29%) with both of these measurements, 
which limits our power to detect differences in the association between urinary melatonin 
and breast cancer by MT1R subtype. Moreover, because of this small number of cases, we 
were unable to examine these associations for in situ cases separately. In addition, there are 
limitations with our measurements of urinary melatonin levels and MT1R subtyping. 
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Because urine was collected at only one point in time, it is possible that melatonin levels at 
that time may not reflect melatonin levels over time; however, previous research has 
established that urinary melatonin levels are highly correlated over three years in this cohort 
(intraclass correlation=0.72), which lends more credibility to the notion that one-time 
melatonin assessment might contain relevant information about longer-term melatonin 
levels(20). For MT1R subtyping, there is little established information on the optimal cut 
point for characterizing positivity of this tumor marker. Thus, in our study, we utilized 
several different approaches to this definition, including ones based on a comparison of 
pathologist vs. machine read values, as well as absolute and relative values of our 
distribution. Results were similar comparing these various approaches, and therefore this 
limitation is less likely to have affected our interpretation of results. Finally, we assessed 
MT1R expression of breast tumors because this receptor is thought to largely mediate 
melatonin’s anti-cancer effects; however, it is possible that expression of MT2R and key 
downstream signaling proteins play an important role in mediating this association, and we 
have not assessed these tumor factors in our cohort(18).
In summary, higher melatonin levels were associated with reduced breast cancer risk in 
postmenopausal women—consistent with our previous finding based on shorter follow up in 
this cohort. Moreover, there was no difference in the association comparing MT1R-positive 
vs. negative breast tumors. Future research should evaluate these associations with longer-
term follow up, a larger number of cases with MT1R subtyping, and among premenopausal 
women.
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Table 1
Baseline characteristics (at urine collection in 2000) of breast cancer cases (n=555), including by MT1R 
subtype (n=158), and matched controls (n=799)






Mean melatonin level, in ng/mg creatinine (SD) 29.8 (30.7) 26.6 (25.9) 29.1 (28.7) 24.2 (34.0)
Mean age, in years (SD) a 66.9 (6.8) 66.6 (6.8) 67.4 (7.1) 66.9 (6.5)
Mean age at menarche, in years (SD) 12.6 (1.4) 12.5 (1.4) 12.6 (1.3) 12.4 (1.4)
Mean age at menopause, in years (SD) 49.6 (4.7) 50.3 (5.0) 50.4 (4.3) 50.5 (4.7)
Mean number of births (SD) 3.2 (1.6) 3.1 (1.4) 3.2 (1.5) 3.1 (1.3)
Family history of breast cancer, % 16 23 23 21
Mean BMI, in kg/m2 (SD) 26.4 (5.2) 26.8 (5.0) 26.8 (4.7) 27.3 (4.8)
Mean alcohol intake, in g/day (SD) 5.3 (8.5) 6.3 (9.8) 5.8 (9.1) 6.8 (11.8)
Current smoker, % 4 6 9 3
History of benign breast disease, % 59 65 63 60
Recent PMH use, % a 56 66 73 66
Duration of PMH use (estrogen only), %
 None 58 63 54 72
 <5 years 13 10 11 15
 ≥5 years 29 27 35 13
Duration of PMH use (estrogen + progesterone), %
 None 62 54 56 52
 <5 years 15 14 6 15
 ≥5 years 23 32 38 33
First morning urine, % 95 93 97 97
ER+/PR+ tumor, % n/a 74 78 75
a
These are matching factors.
SD=standard deviation
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Table 2
Baseline characteristics (at urine collection in 2000) of matched controls across quartiles of creatinine-
standardized urinary melatonin level (n=799)
Quartiles of urinary melatonin levels (in ng/mg creatinine)
Characteristic Quartile 1 Quartile 2 Quartile 3 Quartile 4
Mean melatonin level, in ng/mg creatinine (SD) 6.9 (3.0) 17.6 (3.4) 30.3 (4.3) 64.8 (44.2)
Mean age, in years (SD) 67.9 (6.6) 67.5 (6.6) 66.1 (6.9) 66.2 (6.9)
Mean age at menarche, in years (SD) 12.6 (1.4) 12.6 (1.3) 12.6 (1.3) 12.6 (1.4)
Mean age at menopause, in years (SD) 49.4 (4.4) 49.4 (5.3) 49.7 (4.2) 49.8 (4.9)
Mean number of births (SD) 3.3 (1.6) 3.2 (1.8) 3.2 (1.5) 3.3 (1.5)
Family history of breast cancer, % 14 17 13 19
Mean BMI, in kg/m2 (SD) 27.6 (5.8) 26.9 (5.4) 25.9 (4.9) 25.3 (4.1)
Mean alcohol intake, in g/day (SD) 5.5 (9.0) 4.9 (8.8) 5.9 (8.7) 4.9 (7.3)
Current smoker, % 7 3 3 4
History of benign breast disease, % 61 61 50 61
Recent PMH use, % 54 58 56 58
Duration of PMH use (estrogen only), %
 None 58 57 57 59
 <5 years 13 15 12 12
 ≥5 years 29 28 31 29
Duration of PMH use (estrogen + progesterone), %
 None 62 61 62 63
 <5 years 19 13 17 12
 ≥5 years 19 26 21 25
First morning urine, % 94 97 96 95
SD=standard deviation
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